ArticleVirus research2026
Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against respiratory syncytial virus.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human respiratory syncytial virus (RSV) is a ubiquitous pathogen belonging to the Pneumoviridae family. The enveloped virion contains a negative-sense single-stranded RNA genome comprising 10 genes. Infection is crucially dependent on the RSV fusion (F)-protein, which mediates fusion between the viral envelope and airway epithelial cells; F-protein is also responsible for fusion of infected cells with adjacent cells, leading to syncytium formation. RSV is the leading cause of hospitalization in young children with acute respiratory infections, and can be life-threatening particularly in infants under 6-months. RSV is also recognized to cause a substantial health burden in older adults. Virus-triggered exacerbated inflammation is associated with severe RSV disease outcomes. Although several F-targeting vaccines and monoclonal antibodies are now available for prevention of RSV disease, there is no effective specific drug treatment for RSV. Herein we show that the non-steroidal anti-inflammatory drug indomethacin possesses antiviral activity against RSV, causing a decrease in infectious virus production in different types of human respiratory cells at low micromolar concentrations. Indomethacin does not affect RSV adsorption or entry into host cells, but acts at the post-entry stage by interfering with F-protein expression. Whereas indomethacin anti-inflammatory action is mediated by cyclooxygenase-1 and -2 (COX-1/2) inhibition, the anti-RSV activity is not mimicked by the potent COX-1/2 inhibitor aspirin, indicating a cyclooxygenase-independent effect. The results suggest that indomethacin, possessing a direct antiviral activity against RSV in addition to anti-inflammatory properties, may provide a useful tool for the treatment of RSV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.